Infective endocarditis by Nocardia species: a systematic review. 2023

Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
Department of Internal Medicine & Infectious Diseases, University Hospital of Heraklion, Heraklion, Greece.

Nocardiosis, is a potentially life-threatening disease, especially in immunocompromised individuals where it manifests as a disseminated disease. Infective Endocarditis (IE) is a rare disease with significant morbidity and mortality. Importantly, even though there are scarce data of IE by Nocardia spp. in the literature, a review adequately summarizing systematically all available evidence on the topic is lacking. The aim of this study was to systematically review all cases of IE by Nocardia spp. and describe the epidemiology, microbiology, clinical characteristics, treatment and outcomes of this infection. A systematic review of PubMed, Scopus and Cochrane library (through 7 December 2021) for studies providing epidemiological, clinical, microbiological as well as treatment data and outcomes of patients with IE by Nocardia spp. was performed. A total of 25 studies providing data for 26 patients were included. A prosthetic valve was present in 30.8%, while the most common microorganism was N. asteroides. Aortic valve was the most commonly infected intracardiac site, followed by the mitral valve. Diagnosis was most commonly performed with transthoracic echocardiography, while the diagnosis was made at autopsy in 11.5%. Co-trimoxazole, aminoglycosides and carbapenems were the most commonly used antimicrobials. Clinical cure was noted in 73.1%, while mortality was 26.9%. This systematic review thoroughly describes IE by Nocardia and provides information on epidemiology, clinical presentation, treatment and outcomes.

UI MeSH Term Description Entries
D009615 Nocardia A genus of gram-positive, aerobic bacteria whose species are widely distributed and are abundant in soil. Some strains are pathogenic opportunists for humans and animals. Micropolyspora
D004696 Endocarditis Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening. Infective Endocarditis,Endocarditides,Endocarditides, Infective,Endocarditis, Infective,Infective Endocarditides
D004697 Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use. Bacterial Endocarditides,Bacterial Endocarditis,Endocarditides, Bacterial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D015662 Trimethoprim, Sulfamethoxazole Drug Combination A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS. Trimethoprim-Sulfamethoxazole Combination,Abactrim,Bactifor,Bactrim,Biseptol,Biseptol-480,Centran,Centrin,Co-Trimoxazole,Cotrimoxazole,Drylin,Eslectin,Eusaprim,Insozalin,Kepinol,Kepinol Forte,Lescot,Metomide,Oriprim,Septra,Septrin,Sulfamethoxazole-Trimethoprim Combination,Sulprim,Sumetrolim,TMP SMX,TMP-SMX,Trimedin,Trimethoprim-Sulfamethoxazole,Trimethoprimsulfa,Trimezole,Trimosulfa,Biseptol 480,Biseptol480,Co Trimoxazole,Sulfamethoxazole Trimethoprim Combination,Trimethoprim Sulfamethoxazole,Trimethoprim Sulfamethoxazole Combination

Related Publications

Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
September 2020, Germs,
Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
February 2021, Tropical medicine and infectious disease,
Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
October 2021, Journal of chemotherapy (Florence, Italy),
Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
July 2021, Journal of chemotherapy (Florence, Italy),
Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
August 2022, Journal of clinical medicine,
Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
October 2022, Journal of chemotherapy (Florence, Italy),
Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
April 2023, Journal of chemotherapy (Florence, Italy),
Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
March 2022, Journal of clinical medicine,
Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
February 2024, Medicina (Kaunas, Lithuania),
Antonios Velidakis, and Fotios Degaitis, and George Tsorbatzoglou, and Petros Ioannou
January 2024, Antibiotics (Basel, Switzerland),
Copied contents to your clipboard!